7 Results for "

CHO cells,obesity

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "CHO cells,obesity" in MCE Product Catalog:

Cat. No.: HY-P4146
CAS No.: 2805997-46-8
Synonyms: BI 456906
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
loading...
    loading...
Cat. No.: HY-P4146A
Synonyms: BI 456906 TFA
Target:  

GLP Receptor GCGR

Research Areas:  

Metabolic Disease

Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
loading...
    loading...
Cat. No.: HY-P4146B
Synonyms: BI 456906 sodium
Target:  

GLP Receptor GCGR

Research Areas:  

Metabolic Disease

Survodutide (BI 456906) sodium is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide sodium, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide sodium has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
loading...
    loading...
Cat. No.: HY-P0165B
CAS No.: 1022150-16-8
Synonyms: ITM077 acetate; R1583 acetate; BIM51077 acetate
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
loading...
    loading...
Cat. No.: HY-186050
CAS No.: 3105300-99-7
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

GIPR antagonist 2 is a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist with an IC50 of 7.2 nM in CHO-K1 cells. GIPR antagonist 2 can be used in research related to diseases such as obesity, type 2 diabetes, non-alcoholic fatty liver disease, and atherosclerosis .
loading...
    loading...
Cat. No.: HY-P12143
Target:  

GCGR GLP Receptor

Research Areas:  

Metabolic Disease

GCGR/GLP‐1 receptor agonist P1 is a dual GCGR/GLP-1R agonist. GCGR/GLP‐1 receptor agonist P1 activates human GCGR in vitro and induces the cyclic adenosine monophosphate (cAMP) signaling pathway. GCGR/GLP‐1 receptor agonist P1 is applicable to research related to type 2 diabetes and obesity .
loading...
    loading...
Cat. No.: HY-P11584
Research Areas:  

Metabolic Disease

KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity .
loading...
    loading...